Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
10. December 2024

Does ST-Elevation MI Need a Rebrand to ‘Occlusion MI’? (The Bob Harrington Show, Medscape Cardiology, by Dr. Robert Harrington)

Smartphone screen showing Medscape’s Bob Harrington Show episode “Does ST-Elevation MI Need a Rebrand to ‘Occlusion MI’?” with expert cardiology discussion

About the Podcast

The Bob Harrington Show on Medscape Cardiology brings leading voices in cardiovascular medicine together to discuss evolving evidence, clinical paradigms, and future directions in patient care. Hosted by Dr. Robert Harrington, the show features thought-provoking conversations with renowned experts.

Summary of the Episode

In this episode, Dr. Harrington speaks with Dr. C. Michael Gibson (Harvard/Baim Institute) and Dr. Manesh Patel (Duke University) about the shifting paradigm from ST-Elevation MI (STEMI) to Occlusion MI (OMI).

  • Relying solely on ST-segment elevation misses many patients with an occluded artery, including posterior infarcts, transient occlusions, and subtle cases.
  • False alarms and delays remain challenges: ~30–40% of STEMI cath lab activations may be “false positives,” yet many of these cases still involve dynamic coronary occlusion.
  • The future of acute MI diagnosis will likely combine AI-based ECG interpretation, home and wearable monitoring, and biomarker detection to catch occlusions earlier.
  • Panelists emphasized the need for a clinical shift: focus less on ECG labels and more on whether an artery is closed and needs urgent reperfusion.

“It’s time to move beyond ST elevation. The real question is: is the artery closed? If so, patients need timely intervention — whether or not the ECG shows elevation.”
— Dr. C. Michael Gibson, The Bob Harrington Show

🎧 Listen to the episode: Official page | Spotify | Apple Podcasts

Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
About PMcardio:

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

Share this article

Don't miss these

Powerful Medical team receiving the MedTech Innovator 2025 Mid-Stage Grand Prize award on stage, holding a large winner’s check.

Powerful Medical Wins MedTech Innovator 2025

Powerful Medical has been named MedTech Innovator 2025, winning MTI’s Mid-Stage Grand Finals—top honor from the world’s largest medtech accelerator. The award recognizes PMcardio and its FDA Breakthrough-designated Queen of Hearts™ AI ECG technology, which doubles sensitivity for detecting severe heart attacks and significantly cuts ECG-to-balloon time in large clinical trials.

PMcardio Reports Positive RCT Results and Late-Breaking Clinical Science for STEMI Detection

PMcardio’s AI-powered ECG technology delivers breakthrough results at TCT 2025—improving heart attack detection, reducing false activations, and enabling faster treatment across major clinical trials, including the landmark DIFOCCULT-3 RCT.

Join over 100,000 healthcare professionals who are already taking advantage of AI

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.